Nasal immunomodulator for Covid-19

Scientists from Colorado have received approval for a phase II clinical study to test an intranasal drug with respiratory distress syndrome caused by coronavirus. Immunomodulator Ampion (AP-019) has anti-inflammatory effects in addition to immunomodulatory properties. Scientists say AP-019 reduces the overactive immune response associated with Covid-19, and it may improve clinical outcome in patients suffering from Covid complications.

In the final stages of the study, the results showed a 78% reduction in mortality from respiratory distress syndrome compared with the standard of care. Patients, who received the standard of therapy and Ampion concurrently, experienced a 5% mortality rate, compared with 24% in the standard of therapy group.

Source: clinicaltrialsarena